Prevention of HIV-1 transmission through breastfeeding

Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial

Patricia M. Flynn, Taha E. Taha, Mae Cababasay, Mary Glenn Fowler, Lynne M. Mofenson, Maxensia Owor, Susan Fiscus, Lynda Stranix-Chibanda, Anna Coutsoudis, Devasena Gnanashanmugam, Nahida Chakhtoura, Katie McCarthy, Cornelius Mukuzunga, Bonus Makanani, Dhayendre Moodley, Teacler Nematadzira, Bangini Kusakara, Sandesh Patil, Tichaona Vhembo, Raziya Bobat & 7 others Blandina T. Mmbaga, Maysseb Masenya, Mandisa Nyati, Gerhard Theron, Helen Mulenga, Kevin Butler, David E. Shapiro

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of motherto- child transmission throughout the breastfeeding period. Setting: Fourteen sites in Sub-Saharan Africa and India. Methods: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm3 (or $country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infant nevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infant HIV-1 infection at entry. Results: Between June 2011 and October 2014, 2431 mother- infant pairs were enrolled; 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm3. Median infant gestational age/birth weight was 39 weeks/ 2.9 kilograms. Seven of 1219 (0.57%) and 7 of 1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). Conclusions: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.

Original languageEnglish (US)
Pages (from-to)383-392
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume77
Issue number4
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Nevirapine
Breast Feeding
HIV-1
Cell Count
Mothers
Clinical Trials
Safety
Therapeutics
HIV Infections
CD4 Lymphocyte Count
HIV
Survival
Africa South of the Sahara
Random Allocation

Keywords

  • Antiretroviral therapy (ART)
  • Breastfeeding
  • HIV-1
  • Nevirapine
  • Prevention of perinatal HIV-1 transmission

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Prevention of HIV-1 transmission through breastfeeding : Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial. / Flynn, Patricia M.; Taha, Taha E.; Cababasay, Mae; Fowler, Mary Glenn; Mofenson, Lynne M.; Owor, Maxensia; Fiscus, Susan; Stranix-Chibanda, Lynda; Coutsoudis, Anna; Gnanashanmugam, Devasena; Chakhtoura, Nahida; McCarthy, Katie; Mukuzunga, Cornelius; Makanani, Bonus; Moodley, Dhayendre; Nematadzira, Teacler; Kusakara, Bangini; Patil, Sandesh; Vhembo, Tichaona; Bobat, Raziya; Mmbaga, Blandina T.; Masenya, Maysseb; Nyati, Mandisa; Theron, Gerhard; Mulenga, Helen; Butler, Kevin; Shapiro, David E.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 77, No. 4, 01.01.2018, p. 383-392.

Research output: Contribution to journalArticle

Flynn, PM, Taha, TE, Cababasay, M, Fowler, MG, Mofenson, LM, Owor, M, Fiscus, S, Stranix-Chibanda, L, Coutsoudis, A, Gnanashanmugam, D, Chakhtoura, N, McCarthy, K, Mukuzunga, C, Makanani, B, Moodley, D, Nematadzira, T, Kusakara, B, Patil, S, Vhembo, T, Bobat, R, Mmbaga, BT, Masenya, M, Nyati, M, Theron, G, Mulenga, H, Butler, K & Shapiro, DE 2018, 'Prevention of HIV-1 transmission through breastfeeding: Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial', Journal of Acquired Immune Deficiency Syndromes, vol. 77, no. 4, pp. 383-392. https://doi.org/10.1097/QAI.0000000000001612
Flynn, Patricia M. ; Taha, Taha E. ; Cababasay, Mae ; Fowler, Mary Glenn ; Mofenson, Lynne M. ; Owor, Maxensia ; Fiscus, Susan ; Stranix-Chibanda, Lynda ; Coutsoudis, Anna ; Gnanashanmugam, Devasena ; Chakhtoura, Nahida ; McCarthy, Katie ; Mukuzunga, Cornelius ; Makanani, Bonus ; Moodley, Dhayendre ; Nematadzira, Teacler ; Kusakara, Bangini ; Patil, Sandesh ; Vhembo, Tichaona ; Bobat, Raziya ; Mmbaga, Blandina T. ; Masenya, Maysseb ; Nyati, Mandisa ; Theron, Gerhard ; Mulenga, Helen ; Butler, Kevin ; Shapiro, David E. / Prevention of HIV-1 transmission through breastfeeding : Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial. In: Journal of Acquired Immune Deficiency Syndromes. 2018 ; Vol. 77, No. 4. pp. 383-392.
@article{39886444442b45d090acafc41154b4bf,
title = "Prevention of HIV-1 transmission through breastfeeding: Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial",
abstract = "Background: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of motherto- child transmission throughout the breastfeeding period. Setting: Fourteen sites in Sub-Saharan Africa and India. Methods: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm3 (or $country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infant nevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infant HIV-1 infection at entry. Results: Between June 2011 and October 2014, 2431 mother- infant pairs were enrolled; 97{\%} of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm3. Median infant gestational age/birth weight was 39 weeks/ 2.9 kilograms. Seven of 1219 (0.57{\%}) and 7 of 1211 (0.58{\%}) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96{\%} repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1{\%}, mART and 97.7{\%}, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). Conclusions: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.",
keywords = "Antiretroviral therapy (ART), Breastfeeding, HIV-1, Nevirapine, Prevention of perinatal HIV-1 transmission",
author = "Flynn, {Patricia M.} and Taha, {Taha E.} and Mae Cababasay and Fowler, {Mary Glenn} and Mofenson, {Lynne M.} and Maxensia Owor and Susan Fiscus and Lynda Stranix-Chibanda and Anna Coutsoudis and Devasena Gnanashanmugam and Nahida Chakhtoura and Katie McCarthy and Cornelius Mukuzunga and Bonus Makanani and Dhayendre Moodley and Teacler Nematadzira and Bangini Kusakara and Sandesh Patil and Tichaona Vhembo and Raziya Bobat and Mmbaga, {Blandina T.} and Maysseb Masenya and Mandisa Nyati and Gerhard Theron and Helen Mulenga and Kevin Butler and Shapiro, {David E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/QAI.0000000000001612",
language = "English (US)",
volume = "77",
pages = "383--392",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "4",

}

TY - JOUR

T1 - Prevention of HIV-1 transmission through breastfeeding

T2 - Efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high cd4 cell count (IMPAACT PROMISE): A randomized, open-label, clinical trial

AU - Flynn, Patricia M.

AU - Taha, Taha E.

AU - Cababasay, Mae

AU - Fowler, Mary Glenn

AU - Mofenson, Lynne M.

AU - Owor, Maxensia

AU - Fiscus, Susan

AU - Stranix-Chibanda, Lynda

AU - Coutsoudis, Anna

AU - Gnanashanmugam, Devasena

AU - Chakhtoura, Nahida

AU - McCarthy, Katie

AU - Mukuzunga, Cornelius

AU - Makanani, Bonus

AU - Moodley, Dhayendre

AU - Nematadzira, Teacler

AU - Kusakara, Bangini

AU - Patil, Sandesh

AU - Vhembo, Tichaona

AU - Bobat, Raziya

AU - Mmbaga, Blandina T.

AU - Masenya, Maysseb

AU - Nyati, Mandisa

AU - Theron, Gerhard

AU - Mulenga, Helen

AU - Butler, Kevin

AU - Shapiro, David E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of motherto- child transmission throughout the breastfeeding period. Setting: Fourteen sites in Sub-Saharan Africa and India. Methods: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm3 (or $country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infant nevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infant HIV-1 infection at entry. Results: Between June 2011 and October 2014, 2431 mother- infant pairs were enrolled; 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm3. Median infant gestational age/birth weight was 39 weeks/ 2.9 kilograms. Seven of 1219 (0.57%) and 7 of 1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). Conclusions: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.

AB - Background: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of motherto- child transmission throughout the breastfeeding period. Setting: Fourteen sites in Sub-Saharan Africa and India. Methods: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm3 (or $country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infant nevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infant HIV-1 infection at entry. Results: Between June 2011 and October 2014, 2431 mother- infant pairs were enrolled; 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm3. Median infant gestational age/birth weight was 39 weeks/ 2.9 kilograms. Seven of 1219 (0.57%) and 7 of 1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). Conclusions: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.

KW - Antiretroviral therapy (ART)

KW - Breastfeeding

KW - HIV-1

KW - Nevirapine

KW - Prevention of perinatal HIV-1 transmission

UR - http://www.scopus.com/inward/record.url?scp=85048572083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048572083&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001612

DO - 10.1097/QAI.0000000000001612

M3 - Article

VL - 77

SP - 383

EP - 392

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 4

ER -